Literature DB >> 11559373

Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life.

W C McCormick1, J Hardy, W A Kukull, J D Bowen, L Teri, S Zitzer, E B Larson.   

Abstract

OBJECTIVES: To learn whether managed care patients with Alzheimer's disease (AD) are more or less costly to care for than patients with other forms of dementia or patients without dementia during the last few years of life.
DESIGN: Case control study.
SETTING: A health maintenance organization base population. PARTICIPANTS: Three groups of subjects (mean age 85) who were deceased members of a dementia registry obtained from a health maintenance organization base population: 263 subjects with clinically diagnosed probable AD, 133 subjects with other forms of dementia, and 100 cognitively intact controls. MEASUREMENTS: Utilization records were examined for the 3 years preceding death.
RESULTS: In all subcategories and in aggregate, utilization and costs of care were either similar or lower for patients with AD than for the other groups, even after controlling for age, gender, and comorbidity.
CONCLUSIONS: Persons with AD do not incur higher costs than persons with other types of dementia or age-matched persons without dementia in a mature health maintenance organization during the last few years of life, when utilization is likely to be highest.

Entities:  

Mesh:

Year:  2001        PMID: 11559373     DOI: 10.1046/j.1532-5415.2001.49231.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  29 in total

1.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

Review 3.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

4.  Care coordination for cognitively impaired older adults and their caregivers.

Authors:  Mary D Naylor; Karen B Hirschman; Kathryn H Bowles; M Brian Bixby; JoAnne Konick-McMahan; Caroline Stephens
Journal:  Home Health Care Serv Q       Date:  2007

Review 5.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

Review 6.  Dementia and co-occurring chronic conditions: a systematic literature review to identify what is known and where are the gaps in the evidence?

Authors:  Mark B Snowden; Lesley E Steinman; Lucinda L Bryant; Monique M Cherrier; Kurt J Greenlund; Katherine H Leith; Cari Levy; Rebecca G Logsdon; Catherine Copeland; Mia Vogel; Lynda A Anderson; David C Atkins; Janice F Bell; Annette L Fitzpatrick
Journal:  Int J Geriatr Psychiatry       Date:  2017-02-01       Impact factor: 3.485

Review 7.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 8.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 9.  New strategies for Alzheimer's disease and cognitive impairment.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

10.  Dementia and out-of-pocket spending on health care services.

Authors:  Adeline Delavande; Michael D Hurd; Paco Martorell; Kenneth M Langa
Journal:  Alzheimers Dement       Date:  2012-11-13       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.